- Trials with a EudraCT protocol (2)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
2 result(s) found for: CX3CR1.
Displaying page 1 of 1.
EudraCT Number: 2008-007177-20 | Sponsor Protocol Number: Sirolimus_Liver_Tolerance | Start Date*: 2009-09-07 | |||||||||||
Sponsor Name:Hospital Clinic Barcelona | |||||||||||||
Full Title: EFECTO DEL SIROLIMUS SOBRE LOS BIOMARCADORES RELACIONADOS CON LA TOLERANCIA EN RECEPTORES DE TRASPLANTE HEPĂTICO ESTABLES | |||||||||||||
Medical condition: Stable liver transplant recipients identified as non-tolerant (i.e. requiring indefinite immunosuppressive therapy) on the basis of peripheral blood transcriptional biomarkers. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001857-14 | Sponsor Protocol Number: UC-0101/1709 | Start Date*: 2018-04-18 |
Sponsor Name:UNICANCER | ||
Full Title: A phase I/II basket trial evaluating a combination of Metronomic Oral Vinorelbine plus anti-PD-L1/anti-CTLA4 ImmunothErapy in patients with advanced solid tumours. | ||
Medical condition: Patients with Histologically confirmed locally advanced or metastatic solid tumours, resistant to conventional therapies, and candidate to experimental therapy by local clinical board, from the fol... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
